JP2023514742A5 - - Google Patents
Info
- Publication number
- JP2023514742A5 JP2023514742A5 JP2022550805A JP2022550805A JP2023514742A5 JP 2023514742 A5 JP2023514742 A5 JP 2023514742A5 JP 2022550805 A JP2022550805 A JP 2022550805A JP 2022550805 A JP2022550805 A JP 2022550805A JP 2023514742 A5 JP2023514742 A5 JP 2023514742A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pbn
- composition according
- therapeutically effective
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980645P | 2020-02-24 | 2020-02-24 | |
| US62/980,645 | 2020-02-24 | ||
| PCT/US2021/019457 WO2021173702A1 (en) | 2020-02-24 | 2021-02-24 | Compositions and methods for treating cancer and tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514742A JP2023514742A (ja) | 2023-04-07 |
| JP2023514742A5 true JP2023514742A5 (enExample) | 2024-03-04 |
Family
ID=77490220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550805A Pending JP2023514742A (ja) | 2020-02-24 | 2021-02-24 | がん及び腫瘍を処置する組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230092005A1 (enExample) |
| EP (1) | EP4110315A4 (enExample) |
| JP (1) | JP2023514742A (enExample) |
| KR (1) | KR20220145861A (enExample) |
| CN (1) | CN115151250A (enExample) |
| AU (1) | AU2021228654A1 (enExample) |
| CA (1) | CA3168980A1 (enExample) |
| WO (1) | WO2021173702A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| WO2009102808A2 (en) * | 2008-02-12 | 2009-08-20 | Tosk, Incorporated | Doxorubicin adjuvants to reduce toxicity and methods for using the same |
| AU2009288057B2 (en) * | 2008-09-02 | 2014-07-03 | Oklahoma Medical Research Foundation | 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas |
| WO2012106313A2 (en) * | 2011-01-31 | 2012-08-09 | Oklahoma Medical Research Foundation | Ubiquitin interacting motif peptides as cancer therapeutics |
| EP3570826A4 (en) * | 2017-01-19 | 2020-09-23 | Otologic Pharmaceutics, Inc. | N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES |
| KR101905864B1 (ko) * | 2017-03-20 | 2018-10-08 | 아주대학교산학협력단 | Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물 |
| ES3063479T3 (en) * | 2017-09-20 | 2026-04-16 | Oklahoma Med Res Found | Treatment of drug resistant gliomas |
| EP3787750A1 (en) * | 2018-05-03 | 2021-03-10 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
-
2021
- 2021-02-24 KR KR1020227032630A patent/KR20220145861A/ko active Pending
- 2021-02-24 CA CA3168980A patent/CA3168980A1/en active Pending
- 2021-02-24 WO PCT/US2021/019457 patent/WO2021173702A1/en not_active Ceased
- 2021-02-24 US US17/801,839 patent/US20230092005A1/en active Pending
- 2021-02-24 JP JP2022550805A patent/JP2023514742A/ja active Pending
- 2021-02-24 CN CN202180016676.8A patent/CN115151250A/zh not_active Withdrawn
- 2021-02-24 EP EP21761886.7A patent/EP4110315A4/en active Pending
- 2021-02-24 AU AU2021228654A patent/AU2021228654A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531939A5 (enExample) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| CN104997808A (zh) | 用于治疗癌症的方法和组合物 | |
| Quispe et al. | Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence | |
| EP3027191A1 (en) | Combinations of a btk inhibitor and fluorouracil for treating cancers | |
| KR101628448B1 (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| JP2024516825A5 (enExample) | ||
| CN112691119A (zh) | 一种抗肿瘤组合物及其应用和抗肿瘤药物 | |
| US20230372382A1 (en) | Use of adenosine diphosphate ribose for adjuvant therapy with radiation and/or anti-cancer treatment | |
| JP2022553298A (ja) | 癌を処置する方法 | |
| CN105560239B (zh) | Cx4945作为制备胃癌顺铂耐药放射耐受逆转作用药物的应用 | |
| JP2023514742A5 (enExample) | ||
| US20220313652A1 (en) | Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in manufacture of medicament for treating cancer | |
| WO2018064851A1 (zh) | 低剂量西地那非作为抗肿瘤药物的应用 | |
| US20220323470A1 (en) | Composition and use thereof in the manufacture of medicament for treating cancer | |
| CN116115623A (zh) | 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用 | |
| JP2024516970A5 (enExample) | ||
| CN115869316A (zh) | 伊斯平斯在制备联合抗乳腺癌药物方面的用途 | |
| Grégoire et al. | Combined radiotherapy and chemotherapy from the perspective of the radiation oncologist | |
| JP2007302609A (ja) | 低酸素性細胞放射線増感剤における放射線増感能の増強剤 | |
| CN102247363A (zh) | 一种增加肿瘤细胞对放射线敏感作用的药物 | |
| CN111494371B (zh) | Pyr3的用途 |